Although several immunotherapy biomarkers, such as expression level of programmed cell death ligand 1 (PD-L1), tumor mutational burden (TMB), and tumor-infiltrating T cells [16–20], were identified in different types of cancer, none of them was validated clinically. This evidence concerns the gene CD274 and neoplasm.